The Zhitong Finance App learned that Hanson Pharmaceuticals (03692) rose more than 3%. As of press release, it had risen 3.27% to HK$31.58, with a turnover of HK$897.682 million.

According to the news, Hanson Pharmaceuticals announced that on September 29, 2026, the Group re-submitted a marketing license application (MAA) for the innovative drug ametinib in the European Union (EMA), and on October 7, 2026, the EMA confirmed acceptance of the new MAA and officially initiated a centralized approval process. The indications are: first-line treatment of patients with epidermal growth factor receptor (EGFR) exon 19 or exon 21 (L858R) replacement mutations, and FEGR in adults T790M Treatment of mutation-positive adult patients with advanced NSCLC.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.